Table 2 Clinical features of study participants between October 2013 and April 2014 (n = 81)

1.

Leprosy type (Ridley & Jopling)

 • Indeterminate

0

0

 • TT

1

1.2

 • BT

19

23.5

 • BB

2

2.5

 • BL

49

60.5

 • LL

10

12.3

2.

Leprosy type

 • PB

20

24.7

 • MB

61

75.3

3.

Status of medication

 • On fourth months of MDT-WHO until completion of treatment

61

75.3

 • RFT ≤ 6 months

11

13.6

 • RFT > 6 months-1 year

9

11.1

4.

History of T2R

 • No

50

61.7

 • Yes

31

38.3

5.

Onset of T2R

 • Before MDT-WHO treatment

8

25.8

 • During MDT-WHO treatment

17

54.8

 • After completion of MDT-WHO treatment

6

19.4

6.

Duration of corticosteroid therapy for T2R

 • ≤ 12 weeks

14

45.2

 • > 12 weeks

17

54.8